Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 22, 2014 Phillip Broadwith	Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system.
Chemistry World January 8, 2013 Andrew Turley	Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
Chemistry World April 19, 2013 Sarah Houlton	Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis.
The Motley Fool August 6, 2008 Brian Orelli	Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.
Chemistry World May 29, 2014 Hepeng Jia	Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market.
The Motley Fool February 6, 2008 Brian Orelli	Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward?
The Motley Fool March 30, 2007 Ralph Casale	Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note.
The Motley Fool July 24, 2008 Brian Orelli	Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth.
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
Chemistry World June 9, 2015 Phillip Broadwith	Opko deepens diagnostics with $1.5bn lab buyout Healthcare firm Opko is aiming to enhance its position in diagnostic technology by agreeing to buy clinical diagnostics service BioReference Laboratories.
Bio-IT World March 2006 Michael A. Greeley	The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain.
The Motley Fool April 27, 2011 Brian Orelli	Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby.
The Motley Fool February 8, 2010 Brian Orelli	An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement.
Chemistry World February 22, 2009 Phillip Broadwith	Reading DNA Base by Base A technique to electrically detect individual DNA bases cut from a single strand of DNA has been developed by researchers in the UK.
The Motley Fool October 28, 2009 Brian Orelli	Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.
The Motley Fool August 18, 2010 Luke Timmerman	Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing.
Chemistry World February 21, 2012 Phillip Broadwith	Nanopore sequencing bags its first genome Oxford Nanopore has presented the first complete genome to be sequenced using a nanopore.
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
The Motley Fool June 14, 2010 Bruce Bigelow	Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval.
The Motley Fool September 24, 2008 Brian Orelli	100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
Chemistry World February 3, 2013 Andy Extance	Enzyme draws nanopore protein sequencing nearer US scientists at the University of California, Santa Cruz, have made a key step towards nanopore protein sequencing, thanks to an 'unfoldase' enzyme. Mark Akeson's team exploited this enzyme to unravel proteins and pull them through nanopores.
The Motley Fool July 26, 2007 Brian Orelli	Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit.
The Motley Fool September 18, 2009 Brian Orelli	Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom.
Bio-IT World September 2005 Kevin Davies	Fantastic 454: DNA Sequencing Pyrotechnics In an exciting advance for DNA sequencing technology, a research team at 454 Life Sciences Corp. has essentially sequenced and assembled a bacterial genome sequence based on a mere 4-hour run on the company's proprietary instrument.
The Motley Fool September 27, 2007 Brian Orelli	Foreign Invasion of the Biochip Market A consortium of Japanese companies including Toshiba, and Canon are planning on jointly developing biochips for research and diagnostic purposes.
Bio-IT World February 2007 Robert M. Frederickson	Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform.
Bio-IT World February 18, 2004	Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies
The Motley Fool February 13, 2009 Brian Orelli	Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
The Motley Fool June 27, 2008 Brian Orelli	The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers.
The Motley Fool April 24, 2008 Brian Orelli	Illumina Ignites This biochip maker is on fire.
Bio-IT World November 14, 2003 Julia Boguslavsky	Genome Center in a Box Scientists at 454 Life Sciences developed an integrated end-to-end instrument that performs hundreds of thousands of reactions in parallel -- from sample preparation, amplification, and sequencing to data storage and bioinformatics.
The Motley Fool July 28, 2010 Brian Orelli	Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.
Chemistry World November 20, 2013 Patrick Walter	Two-time chemistry Nobelist Fred Sanger dies Double chemistry Nobel laureate Frederick Sanger died yesterday at the age of 95. The Laboratory of Molecular Biology in Cambridge, UK, where he spent much of his research career confirmed his death this morning.
The Motley Fool January 3, 2012 Alex Planes	Another Entry in the Genome Patent Rumble There's a whole lot of lawsuits going on.
The Motley Fool July 22, 2009 Brian Orelli	Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line.
The Motley Fool October 25, 2007 Brian Orelli	Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter.
The Motley Fool October 24, 2008 Brian Orelli	Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell.
The Motley Fool June 20, 2008 Brian Orelli	Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics.
Bio-IT World October 2005 Dennis A. Gilbert	The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp.
Chemistry World October 29, 2015 Anthony King	Poor diagnostics hinder battle against antibiotic resistance The tools used to diagnose bacterial infections have barely improved since the 1940s.
Bio-IT World March 2007 Michael A. Greeley	Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities.
IEEE Spectrum June 2009 Prachi Patel	Advance in Nanopore Gene Sequencing Magnets help in the quest for the $1000 genome
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
The Motley Fool June 13, 2008 Brian Orelli	China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year.
The Motley Fool August 19, 2011 Alexander Crawford	DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list?
The Motley Fool July 12, 2011 Brian Orelli	Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test.